Fulan Guan, PhD
Associate Research Scientist in PharmacologyDownloadHi-Res Photo
Cards
Appointments
Pharmacology
Primary
Additional Titles
Visiting Research Scientist
Contact Info
Appointments
Pharmacology
Primary
Additional Titles
Visiting Research Scientist
Contact Info
Appointments
Pharmacology
Primary
Additional Titles
Visiting Research Scientist
Contact Info
About
Titles
Associate Research Scientist in Pharmacology
Visiting Research Scientist
Appointments
Pharmacology
Associate Research ScientistPrimary
Other Departments & Organizations
- Pharmacology
Education & Training
- PhD
- Guangzhou University of Traditional Chinese Medici (2002)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Fulan Guan's published research.
Publications Timeline
A big-picture view of Fulan Guan's research output by year.
Caroline Helen Johnson, PhD
Jorge Galán, PhD, DVM
Rong Hu, PhD
12Publications
564Citations
Publications
2023
YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
Lam W, Arammash M, Cai W, Guan F, Jiang Z, Liu S, Cheng P, Cheng Y. YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy. Frontiers In Pharmacology 2023, 14: 1244655. PMID: 37860121, PMCID: PMC10582333, DOI: 10.3389/fphar.2023.1244655.Peer-Reviewed Original ResearchAltmetricConceptsCastration-resistant prostate cancerAR target genesActive compoundsAnti-prostate cancer drugProstate cancerSynergistic effectGlucocorticoid receptorPotential drug candidatesDrug discovery platformRA-VIILuciferase activityKey active compoundsGlucocorticoid receptor inhibitionProstate cancer managementNovel therapeutic agentsRA-VDrug candidatesCompoundsDeprivation therapySafety profileCancer deathExtra-terminal (BET) proteinsGR activityReceptor inhibitionAR inhibition
2021
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
Yang X, Lam W, Jiang Z, Guan F, Han X, Hu R, Cai W, Cheng W, Liu SH, Cheng P, Cai Y, Rattray NJW, Johnson CH, Chen L, Cheng YC. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports 2021, 11: 13482. PMID: 34188068, PMCID: PMC8242098, DOI: 10.1038/s41598-021-91623-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsM1-like macrophage polarizationMacrophage polarizationIDO activityInterferon gammaInnate immunityTumor microenvironmentTraditional Chinese herbal formulationPD-L1 inductionM1-like macrophagesAdaptive immune responsesM2 macrophage polarizationChinese herbal formulationTumor bearing miceQuality of lifeAnti-tumor activityGastrointestinal symptomsMonocytic MDSCsProlong survivalImmune toleranceAcute inflammationCancer patientsClinical resultsHepatocellular carcinomaImmune responseRadiation therapyProspective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China
Wu J, Sun B, Hou L, Guan F, Wang L, Cheng P, Scobell S, Cheng YC, Lam W. Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China. Frontiers In Pharmacology 2021, 11: 615287. PMID: 33716728, PMCID: PMC7947616, DOI: 10.3389/fphar.2020.615287.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTraditional Chinese medicineMaxingshigan decoctionChinese medicineCOVID-19COVID-19 patientsUnique medical needsPublic health measuresNovel coronavirus diseaseBradykinin stormConventional antiviralsHuo-XueAngiotensin systemSystemic inflammationAntiviral effectAntiviral actionIndividual herbsMedical needHealth measuresCoronavirus diseaseUnderlying mechanismOral formulaPathogenesisDiseaseProspective articlesBotanical treatments
2020
Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging
Hou S, He S, Xie J, Li M, Hong M, Guan F, Hu Y, Huang Y, Xu C. Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging. Spectrochimica Acta Part A Molecular And Biomolecular Spectroscopy 2020, 235: 118315. PMID: 32289732, DOI: 10.1016/j.saa.2020.118315.Peer-Reviewed Original ResearchCitations
2018
Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
Lam W, Ren Y, Guan F, Jiang Z, Cheng W, Xu CH, Liu SH, Cheng YC. Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906). Frontiers In Pharmacology 2018, 09: 1324. PMID: 30510512, PMCID: PMC6252377, DOI: 10.3389/fphar.2018.01324.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHerbal productsAnimal studiesMechanism actionChinese medicine formulationAnti-tumor activityGastrointestinal symptomsPatients' qualityClinical studiesTherapeutic indexLuciferase reporter cell lineChinese formulationRadiation treatmentCancer treatmentQuality control platformReporter cell lineMedicine formulationCell linesFaster recoveryAnticancer agentsPharmacological usageClinical batchesTreatmentAssaysIrinotecanAppropriate biological assaysExploring pathogenesis in subjects with subjective Tinnitus having kidney deficiency pattern in terms of Traditional Chinese Medicine based on serum metabolic profiles.
Tan Y, Lu C, Jiang M, Zhao N, Li L, Shen S, Guan F, He B, Xiao C, L A, Cheng S, Zu X, Zhang W, Liu X. Exploring pathogenesis in subjects with subjective Tinnitus having kidney deficiency pattern in terms of Traditional Chinese Medicine based on serum metabolic profiles. Journal Of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association Of Traditional Chinese Medicine, Academy Of Traditional Chinese Medicine 2018, 38: 773-780. PMID: 32185996.Peer-Reviewed Original Research
2016
Tylophorine Analog DCB-3503 Inhibited Cyclin D1 Translation through Allosteric Regulation of Heat Shock Cognate Protein 70
Wang Y, Lam W, Chen SR, Guan FL, Dutchman GE, Francis S, Baker DC, Cheng YC. Tylophorine Analog DCB-3503 Inhibited Cyclin D1 Translation through Allosteric Regulation of Heat Shock Cognate Protein 70. Scientific Reports 2016, 6: 32832. PMID: 27596272, PMCID: PMC5011780, DOI: 10.1038/srep32832.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCyclin D1 translationShock cognate protein 70D1 translationRNA binding motifsHeat shock cognate protein 70Cellular regulatory proteinsNovel regulatory mechanismProtein 70UTR of mRNAsCyclin D1Chaperone activityAllosteric regulationProtein translationRegulatory proteinsElongation stepATP hydrolysisBinding motifRegulatory mechanismsAUUUA motifsMolecular mechanismsCyclin D1 mRNAProcessing complexElevated expressionHsc70MRNAAntibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates
Tsou LK, Lara-Tejero M, RoseFigura J, Zhang ZJ, Wang YC, Yount JS, Lefebre M, Dossa PD, Kato J, Guan F, Lam W, Cheng YC, Galán J, Hang HC. Antibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates. Journal Of The American Chemical Society 2016, 138: 2209-2218. PMID: 26847396, PMCID: PMC4831573, DOI: 10.1021/jacs.5b11575.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVirulence pathwaysType III protein secretionType III secretion system effectorsSpecific plant metabolitesSPI-1 T3SSSecretion system effectorsS. typhimurium invasionSalmonella enterica serovar TyphimuriumSecretion substratesEnterica serovar TyphimuriumTraditional Chinese medicineUnappreciated mechanismPlant metabolitesTyphimurium invasionProtein secretionSerovar TyphimuriumAntibacterial flavonoidsBacterial invasionEpithelial cellsSpecific flavonoidsBacterial growthMedicinal plantsPathwayPotential mechanismsInvasion
2014
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)
Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, Cheng YC. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complementary Medicine And Therapies 2014, 14: 490. PMID: 25510341, PMCID: PMC4302098, DOI: 10.1186/1472-6882-14-490.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAnti-Bacterial AgentsAntineoplastic Agents, PhytogenicBacteriaCamptothecinColonic NeoplasmsDrugs, Chinese HerbalFemaleGranulocyte Colony-Stimulating FactorHumansIntestinal MucosaIntestinesIrinotecanMiceNeutrophil InfiltrationPhytotherapyReceptors, G-Protein-CoupledRNA, MessengerTumor Necrosis Factor-alphaWeight LossConceptsBody weight lossAntibiotic treatmentCPT-11Tumor-bearing miceIntestinal bacteriaIntestinal toxicityStem cell markersAntitumor activityAnimal body weight lossCPT-11-treated miceCell markersMRNA expressionTNF-alpha mRNA expressionWeight lossAntibiotic treatment groupCPT-11 treatmentCytokines G-CSFProgenitor/stem cell markersLactobacillus/EnterococcusIntestinal damageInflammatory processIntestinal bacterial profilesTreatment groupsPCNA stainingTumor allografts
2013
PHY906, a Cancer Adjuvant Therapy, Differentially Affects Inflammation of Different Tissues
Kong A, Lam, Bussom S, Jiang Z, Zhang W, Guan F, Liu S, Cheng Y. PHY906, a Cancer Adjuvant Therapy, Differentially Affects Inflammation of Different Tissues. 2013, 549-562. DOI: 10.1201/b15323-38.Peer-Reviewed Original Research
News
Get In Touch
Contacts
Email